Drug Discovery From Natural Sources

Organic compounds from terrestrial and marine organisms have extensive past and present use in the treatment of many diseases and serve as compounds of interest both in their natural form and as templates for synthetic modification. Over 20 new drugs launched on the market between 2000 and 2005, originating from terrestrial plants, terrestrial microorganisms, marine organisms, and terrestrial vertebrates and invertebrates, are described. These approved substances, representative of very wide chemical diversity, together with several other natural products or their analogs undergoing clinical trials, continue to demonstrate the importance of compounds from natural sources in modern drug discovery efforts.

[1]  C. Starks,et al.  Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations. , 2003 .

[2]  Marcy J. Balunas,et al.  Drug discovery from medicinal plants. , 2005, Life sciences.

[3]  M. Broggini,et al.  Brostallicin: a new concept in minor groove DNA binder development , 2004, Anti-cancer drugs.

[4]  T. Lynch,et al.  A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer , 2005 .

[5]  Tadashi. Sasaki,et al.  Chrysanthemic acid. V. Thermal and photo [3,3]sigmatropic rearrangements in the cis-2,2-dimethyl-3-isobutenylcyclopropyl isocyanate-3,6-dihydro-3,3,6,6-tetramethyl-2H-azepin-2-one system , 1970 .

[6]  Nicholas H Oberlies,et al.  Camptothecin and taxol: historic achievements in natural products research. , 2004, Journal of natural products.

[7]  J. Portugal.  Chartreusin, elsamicin A and related anti-cancer antibiotics. , 2003, Current medicinal chemistry. Anti-cancer agents.

[8]  N. Perry,et al.  Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders , 2003, Phytotherapy research : PTR.

[9]  James B. Mitchell,et al.  Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. , 2003, Cancer research.

[10]  D. Fabbro,et al.  Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. , 2001, Cancer research.

[11]  Walter Sneader,et al.  Drug Discovery (The History) , 2005 .

[12]  D. Weisleder,et al.  Structures of harringtonine, isoharringtonine, and homoharringtonine. , 1970, Tetrahedron letters.

[13]  Y. Chin,et al.  The role of pharmacognosy in modern medicine and pharmacy. , 2006, Current drug targets.

[14]  K. Nagashima,et al.  A new antifungal antibiotic, trichostatin. , 1976, The Journal of antibiotics.

[15]  P. Jensen,et al.  Marine Microorganisms and Drug Discovery: Current Status and Future Potential , 2000 .

[16]  C. Perry,et al.  Caspofungin: a review of its use in the treatment of fungal infections. , 2005, Drugs.

[17]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[18]  Raoul Herbrecht,et al.  Caspofungin: the first representative of a new antifungal class. , 2003, The Journal of antimicrobial chemotherapy.

[19]  R. Sellers,et al.  Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  M. Fukuoka,et al.  Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer , 2005, Investigational New Drugs.

[21]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[23]  T. Shiraga,et al.  Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.

[24]  D J Newman,et al.  The influence of natural products upon drug discovery. , 2000, Natural product reports.

[25]  E. Estey,et al.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.

[26]  T. Mcmorris,et al.  FUNGAL METABOLITES. THE STRUCTURES OF THE NOVEL SESQUITERPENOIDS ILLUDIN-S AND -M. , 1965, Journal of the American Chemical Society.

[27]  F. Arcamone,et al.  Experimental studies on distamycin A--a new antibiotic with cytotoxic activity. , 1962, Cancer chemotherapy reports.

[28]  N. Farnsworth,et al.  The value of plants used in traditional medicine for drug discovery. , 2001, Environmental health perspectives.

[29]  J. Veitch,et al.  Biosynthesis of elsamicin A, a novel antitumor antibiotic. , 1989, Journal of natural products.

[30]  G. Forni,et al.  α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Pastores,et al.  An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. , 2005, Clinical therapeutics.

[32]  Jieping Zhu,et al.  Synthetic studies toward ecteinascidin 743. , 2005, The Journal of organic chemistry.

[33]  E. Vokes,et al.  Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers , 2005, Investigational New Drugs.

[34]  B. Cheson,et al.  Homoharringtonine: History, current research, and future directions , 2001 .

[35]  G. Mor,et al.  Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells , 2003, Oncogene.

[36]  David J Newman,et al.  Advanced preclinical and clinical trials of natural products and related compounds from marine sources. , 2004, Current medicinal chemistry.

[37]  P. Parsons,et al.  Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. , 2004, Cancer research.

[38]  D. Figgitt,et al.  Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. , 2003, Drugs.

[39]  J. Forrest,et al.  Squalamine: an aminosterol antibiotic from the shark. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Forenza,et al.  Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. , 2002, Current medicinal chemistry. Anti-cancer agents.

[41]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[42]  David J Newman,et al.  Marine natural products and related compounds in clinical and advanced preclinical trials. , 2004, Journal of natural products.

[43]  T. Fojo,et al.  Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. , 2004, Molecular cancer therapeutics.

[44]  M. Heinrich,et al.  Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. , 2004, Journal of ethnopharmacology.

[45]  J. Charrow,et al.  Guidance on the use of miglustat for treating patients with type 1 Gaucher disease , 2005, American journal of hematology.

[46]  S. Eksborg,et al.  Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. , 2001, British journal of clinical pharmacology.

[47]  M. Ledizet,et al.  Discovery and pre-clinical development of antithrombotics from hematophagous invertebrates. , 2005, Current medicinal chemistry. Cardiovascular and hematological agents.

[48]  M. Ratain,et al.  Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor , 2004, Investigational New Drugs.

[49]  O. Tanaka,et al.  On genuine sapogenin of ginseng , 1963 .

[50]  T. Mcmorris,et al.  (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. , 1996, Journal of natural products.

[51]  D. C. Holt,et al.  Mesotrione: a new selective herbicide for use in maize. , 2001, Pest management science.

[52]  C. Deboer,et al.  Geldanamycin, a new antibiotic. , 1970, The Journal of antibiotics.

[53]  D. Deleu,et al.  Subcutaneous Apomorphine , 2004, Drugs & aging.

[54]  M. Jordan,et al.  The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth , 2005, Molecular Cancer Therapeutics.

[55]  Ann Thayer.  BRISTOL-MYERS TO SETTLE SUITS: Drug firm strikes deals with states and others in generics antitrust cases , 2003 .

[56]  Jeffrey W. Clark,et al.  Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  T. Natori,et al.  Agelasphins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas mauritianus , 1994 .

[58]  T. Eggelte,et al.  Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. , 1999, Trends in pharmacological sciences.

[59]  A. Kinghorn,et al.  The discovery of drugs from higher plants. , 1994, Biotechnology.

[60]  J. Raufman,et al.  Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini , 1992, Regulatory Peptides.

[61]  E. Chun,et al.  Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model , 2005, International journal of cancer.

[62]  C. D. Thompson,et al.  A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  D. Bonatto,et al.  Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. , 2005, Biochemical pharmacology.

[64]  R. Capon.  Marine Bioprospecting − Trawling for Treasure and Pleasure , 2001 .

[65]  C. West,et al.  Combretastatin A4 phosphate. , 2004, Anti-cancer drugs.

[66]  Jian Wang,et al.  ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven* , 2004, Journal of Biological Chemistry.

[67]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[68]  J. Sloan,et al.  A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non–Small-Cell Lung Cancer , 2003, American journal of clinical oncology.

[69]  E. Sausville,et al.  7-Hydroxystaurosporine (UCN-01) Inhibition of Akt Thr308 but not Ser473 Phosphorylation , 2004, Clinical Cancer Research.

[70]  Mark S Butler,et al.  The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.

[71]  A. Husband,et al.  Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. , 2003, European journal of cancer.

[72]  M. Broggini,et al.  Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. , 2002, Cancer research.

[73]  M. Butler.  Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.

[74]  G. Giaccone,et al.  Kahalalide F Induces Necrosis-Like Cell Death that Involves Depletion of ErbB3 and Inhibition of Akt Signaling , 2005, Molecular Pharmacology.

[75]  E. Rubin,et al.  Epothilones: mechanism of action and biologic activity. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Mann,et al.  Combretastatins: from natural products to drug discovery. , 2003, Natural product reports.

[77]  J. A. Ross,et al.  PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. , 2003, Molecular cancer therapeutics.

[78]  R. Cerny,et al.  Isolation and Structure of the Cytostatic Linear Depsipeptide Dolastatin 15 , 1989 .

[79]  S. Samuel,et al.  Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. , 2005, Clinical therapeutics.

[80]  P. Atadja,et al.  Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824 , 2004, Cancer Research.

[81]  J. Arts,et al.  Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. , 2003, Current medicinal chemistry.

[82]  M. Siegel,et al.  Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1I , 1987 .

[83]  J. Karlowsky,et al.  The Glycylcyclines , 2004, Drugs.

[84]  Gurmeet Kaur,et al.  Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin , 2004, Clinical Cancer Research.

[85]  T. Gladwell.  Bivalirudin: a direct thrombin inhibitor. , 2002, Clinical therapeutics.

[86]  P. Finn,et al.  Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.

[87]  P. Blumberg,et al.  Characterization of the interaction of ingenol 3-angelate with protein kinase C. , 2004, Cancer research.

[88]  E. Perez,et al.  Phase II trial of dolastatin-10 in patients with advanced breast cancer , 2005, Investigational New Drugs.

[89]  K. Fukasawa,et al.  Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. , 1999, Cancer research.

[90]  J. Ávila,et al.  The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. , 2000, Cancer letters.

[91]  Ian Paterson,et al.  The Renaissance of Natural Products as Drug Candidates , 2005, Science.

[92]  K. Au,et al.  A new antibiotic? , 1969, Biochemical pharmacology.

[93]  B. Cravatt,et al.  Protein-reactive natural products. , 2005, Angewandte Chemie.

[94]  D. Fabbro,et al.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[95]  K. Rinehart,et al.  Geldanamycin. I. Structure assignment. , 1970, Journal of the American Chemical Society.

[96]  T. Lynch,et al.  P-565 A Phase II study of KOS-862 (Epothilone D) as second-linetherapy in non-small cell lung cancer , 2005 .

[97]  M. Ogawa.  Novel anticancer drugs in Japan , 1999, Journal of Cancer Research and Clinical Oncology.

[98]  D. Ribatti,et al.  Antiangiogenic activity of aplidine, a new agent of marine origin , 2004, British Journal of Cancer.

[99]  Kenneth B. Tomer,et al.  The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10 , 1987 .

[100]  K. Rinehart.  Antitumor compounds from tunicates , 2000, Medicinal research reviews.

[101]  Y. Suárez,et al.  Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. , 2003, Molecular cancer therapeutics.

[102]  C. Schroeder,et al.  Development of small molecules that mimic the binding of ω-conotoxins at the N-type voltage-gated calcium channel , 2004, Molecular Diversity.

[103]  A. Ravaud,et al.  Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. , 2003, European journal of cancer.

[104]  P. Kosmidis,et al.  Advanced NSCLC: new cytostatic agents. , 2003, Lung cancer.

[105]  W. Jia,et al.  Aglycone Protopanaxadiol, a ginseng saponin inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  D. Figgitt,et al.  Rosuvastatin , 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[107]  Burkhard Haefner,et al.  Drugs from the deep: marine natural products as drug candidates. , 2003, Drug discovery today.

[108]  D. Chaplin,et al.  Combretastatin A4 phosphate: background and current clinical status , 2004, Expert opinion on investigational drugs.